Madie sells XLRN 27.31: Acceleron Pharma (NASDAQ:XLRN) last posted its earnings results on Thursday, August 6th.

Finally, Morgan Stanley started coverage on Acceleron Pharma in a research note on Thursday, August 13th. Guggenheim began coverage on Acceleron Pharma in a research report on Tuesday, June 9th. Equities analysts anticipate that Acceleron Pharma will post ($1.20) EPS for the current fiscal year. Quisel sold 5,500 shares of the stock in a transaction on Friday, August 14th. Ertel sold 2,000 shares of Acceleron Pharma stock in a transaction dated Monday, June 15th.


Lauri:
Guggenheim initiated coverage on shares of Acceleron Pharma in a report on Tuesday, June 9th.

Pei:
A number of other brokerages have also issued reports on XLRN.

Jo:
Acceleron Pharma Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases.

Anne:
One analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock.

Penny:
Guggenheim assumed coverage on Acceleron Pharma in a research note on Tuesday, June 9th.

Coral:
Several research firms recently weighed in on XLRN.

Sydney:
The company had revenue of $5.72 million for the quarter, compared to the consensus estimate of $4.23 million.

Danyell:
About Acceleron Acceleron is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutic candidates that regulate cellular growth and repair.

Magdalena:
As of December 31, 2014 the company had cash and cash equivalents of $176.5 million.

Reatha:
Acceleron Research and Development (R&D) Day scheduled for Friday October 23, 2015- Acceleron will hold its first R&D Day on Friday morning, October 23, 2015 in New York City.

Acceleron Pharma Inc. (NASDAQ:XLRN)
//stockhand.net/us/?q=nasdaq%3Axlrn&id=443904